TuisNCYT • LON
Novacyt SA
GBX 54,00
31 Jan., 03:15:43 UTC · GBX · LON · Vrywaring
AandeelGB-gelyste effek
Vorige sluiting
GBX 51,80
Dagwisseling
GBX 52,00 - GBX 55,60
Jaarwisseling
GBX 42,95 - GBX 137,00
Markkapitalisasie
45,48 m EUR
Gemiddelde volume
210,95 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
EPA
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(GBP)Jun. 2024J/J-verandering
Inkomste
5,16 m209,13%
Bedryfskoste
7,92 m92,89%
Netto inkomste
-8,85 m-112,01%
Netto winsgrens
-171,4731,41%
Wins per aandeel
EBITDA
-12,02 m-324,07%
Effektiewe belastingkoers
1,22%
Totale bates
Totale aanspreeklikheid
(GBP)Jun. 2024J/J-verandering
Kontant en korttermynbeleggings
32,95 m-59,69%
Totale bates
99,40 m-24,78%
Totale aanspreeklikheid
28,99 m16,70%
Totale ekwiteit
70,41 m
Uitstaande aandele
70,63 m
Prys om te bespreek
0,52
Opbrengs op bates
-36,30%
Opbrengs op kapitaal
-43,18%
Netto kontantverandering
(GBP)Jun. 2024J/J-verandering
Netto inkomste
-8,85 m-112,01%
Kontant van bedrywe
-4,54 m-59,67%
Kontant van beleggings
-566,50 k-212,18%
Kontant van finansiering
-430,50 k-61,24%
Netto kontantverandering
-5,56 m-112,16%
Beskikbare kontantvloei
-17,73 m-943,16%
Meer oor
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Gestig
2006
Werknemers
240
Search
Vee soektog uit
Maak soekkassie toe
Google-programme
Hoofkieslys